<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206085</url>
  </required_header>
  <id_info>
    <org_study_id>VI-19-01</org_study_id>
    <nct_id>NCT04206085</nct_id>
  </id_info>
  <brief_title>Comparison of the Viveve Treatment and Cryogen-Only Treatment Versus Sham Treatment for Stress Urinary Incontinence</brief_title>
  <official_title>Comparison of the Viveve Treatment and Cryogen-Only Treatment Versus Sham Treatment for Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viveve Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viveve Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, single-blind, study comparing both the Viveve Treatment
      (RF plus cryogen) and cryogen alone treatment versus sham treatment in patients with mild to
      moderate stress urinary incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-hour pad weight test</measure>
    <time_frame>Baseline to 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency and Cryogen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryogen-Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crygen-Only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Viveve - Active</intervention_name>
    <description>Radiofrequency and Cryogen-Cooling</description>
    <arm_group_label>Active treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Viveve - Cryogen-Alone</intervention_name>
    <description>Cryogen-Cooling</description>
    <arm_group_label>Cryogen-Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Viveve - Sham</intervention_name>
    <description>Sham</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-menopausal females, ≥ 18 years of age. Premenopausal is defined as a woman who has
             had menstrual cycles over the previous 12 months.

          -  Subjects with a BMI of ≤ 35 kg/m².

          -  1-hr pad weight at Baseline with a 5 to 50 g net increase from the pre-test pad weight

        Exclusion Criteria:

          -  Subjects who are currently breastfeeding or have discontinued breastfeeding fewer than
             6 months prior to screening.

          -  Subjects who are pregnant or plan to become pregnant during the course of the study.

          -  Subjects who have undergone other stress urinary incontinence treatments, excluding
             behavioral modifications (e.g., Kegel exercises).

          -  Has any implantable electrical device [e.g., implantable pacemaker, automatic
             implantable cardioverter-defibrillator (AICD)].

          -  Subjects who have started or changed dose of local vaginal hormones &lt;6 weeks before
             Screening.

          -  Subjects who have started pelvic floor physical therapy within the last 3 months.

          -  Undergone previous elective surgical or non-invasive procedure(s) in the vaginal canal
             (including the Viveve Treatment or any other genital radiofrequency treatment;
             injectable bulking agent, cosmetic, laser, surgical, and/or genital enhancement
             procedure, and previous dilation and cuterage within 12 months of the subject's
             Pre-Screening Visit).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Milestone Research</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluewater Clinical Research Group</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devonshire Clinical Research</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

